Verubulin (Synonyms: MPC 6827)

目录号: HY-14907 纯度: 99.34%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Verubulin (MPC-6827) 是一种高效、广谱的微管 (microtubule) 阻断剂。Verubulin 对乳腺癌、黑色素瘤和卵巢癌具有抗肿瘤活性。Verubulin 可用于非小细胞肺癌研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Verubulin Chemical Structure

CAS No. : 827031-83-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥880	In-stock
5 mg	￥800	In-stock
10 mg	￥1350	In-stock
50 mg	￥4750	In-stock
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Verubulin:

Verubulin hydrochloride In-stock

Verubulin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research^[1]^[2]^[3].

IC₅₀ & Target

Microtubule^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	0.7 nM Compound: Verubulin	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A375/TxR	IC₅₀	0.7 nM Compound: Verubulin	Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
A-431	IC₅₀	0.9 nM Compound: 1	Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human A-431 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
A549	IC₅₀	0.003 μM Compound: EP128495	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	IC₅₀	0.004 μM Compound: MPC-6827	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
A549	IC₅₀	0.005 μM Compound: MPC6827	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30093295]
A549/CDDP	IC₅₀	0.009 μM Compound: EP128495	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
BJ	IC₅₀	0.015 μM Compound: EP128495	Antiproliferative activity against human BJ cells after 48 hrs by MTT assay Antiproliferative activity against human BJ cells after 48 hrs by MTT assay	[PMID: 29509413]
HCT-116	EC₅₀	0.003 μM Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
HCT-116	IC₅₀	0.004 μM Compound: EP128495	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29509413]
HCT-116	IC₅₀	0.005 μM Compound: MPC-6827	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HCT-116	GI₅₀	0.006 μM Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay Growth inhibition of human HCT116 cells after 48 hrs by celltiter assay	[PMID: 19296653]
HCT-116	IC₅₀	0.009 μM Compound: MPC6827	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30093295]
HCT-116	IC₅₀	4.3 nM Compound: 5; MPC-6827	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 27213819]
HeLa	IC₅₀	0.005 μM Compound: EP128495	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29509413]
HeLa	IC₅₀	0.006 μM Compound: MPC-6827	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HeLa	IC₅₀	0.007 μM Compound: MPC6827	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30093295]
HeLa	IC₅₀	1.5 nM Compound: 1	Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HeLa	IC₅₀	2 nM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
HepG2	IC₅₀	0.005 μM Compound: MPC-6827	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
HepG2	IC₅₀	0.005 μM Compound: EP128495	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	IC₅₀	0.006 μM Compound: MPC6827	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30093295]
HepG2	IC₅₀	4.6 nM Compound: 5; MPC-6827	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 27213819]
L02	IC₅₀	0.013 μM Compound: EP128495	Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay Antiproliferative activity against human LO2 cells after 48 hrs by MTT assay	[PMID: 29509413]
LoVo	IC₅₀	0.008 μM Compound: EP128495	Growth inhibition of human LoVo cells after 48 hrs by MTT assay Growth inhibition of human LoVo cells after 48 hrs by MTT assay	[PMID: 29509413]
M14	IC₅₀	1 nM Compound: Verubulin	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay	[PMID: 34406768]
MCF7	IC₅₀	0.011 μM Compound: EP128495	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-231	IC₅₀	0.008 μM Compound: MPC-6827	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 29673981]
MDA-MB-231	IC₅₀	0.008 μM Compound: EP128495	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29509413]
MDA-MB-435	IC₅₀	1.7 nM Compound: 1	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
MGC-803	IC₅₀	0.008 μM Compound: EP128495	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 29509413]
NCI-H1299	EC₅₀	0.006 μM Compound: 1e	Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
RKO	IC₅₀	0.003 μM Compound: EP128495	Growth inhibition of human RKO cells after 48 hrs by MTT assay Growth inhibition of human RKO cells after 48 hrs by MTT assay	[PMID: 29509413]
RKO	IC₅₀	0.005 μM Compound: MPC6827	Antiproliferative activity against human RKO cells after 48 hrs by MTT assay Antiproliferative activity against human RKO cells after 48 hrs by MTT assay	[PMID: 30093295]
SK-OV-3	IC₅₀	2.2 nM Compound: 1	Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
SK-OV-3	IC₅₀	2.6 nM Compound: 1	Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]
SK-OV-3	IC₅₀	3.2 nM Compound: 5; MPC-6827	Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 27213819]
SNU-398	EC₅₀	0.002 μM Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
SNU-398	GI₅₀	0.003 μM Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay Growth inhibition of human SNU398 cells after 48 hrs by celltiter assay	[PMID: 19296653]
T47D	EC₅₀	0.002 μM Compound: 6h, EP128495,MPC-6827, azixa	Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay	[PMID: 19296653]
T47D	EC₅₀	0.002 μM Compound: 1e	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay	[PMID: 19464890]
T47D	GI₅₀	0.006 μM Compound: 6h, EP128495,MPC-6827, azixa	Growth inhibition of human T47D cells after 48 hrs by celltiter assay Growth inhibition of human T47D cells after 48 hrs by celltiter assay	[PMID: 19296653]
U-251	IC₅₀	2.8 nM Compound: 1	Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability by Sulforhodamine B assay	[PMID: 33647840]

体外研究
(In Vitro)

Verubulin (10 nM；1-3 h) 可快速破坏人 A549 非小细胞肺癌细胞中的微管形成^[2]。
Verubulin (72 h) 可抑制 MCF-7 细胞的生长，IC₅₀ 值为 2.1 nM^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Verubulin (7.5 mg/kg；静脉注射；一次或 1 mg/kg；静脉注射；5 天) 可在 B16 小鼠黑色素瘤模型中诱导肿瘤生长抑制^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic mice (nu/nu), B16 mouse melanoma or OVCAR3 human ovarian cancer cell-implanted subcutaneous xenograft models^[3]
Dosage:	1 mg/kg, 7.5 mg/kg (B16); 2.5, 5 or 10 mg/kg (OVCAR-3)
Administration:	In the B16 study, 7.5 mg/kg was dosed intravenously (i.v.) once, or 1 mg/kg was dosed daily for five days. In the OVCAR-3 study, 5 mg/kg was dosed i.v. once, or 2.5-10 mg/kg/day was dosed intraperitoneally (i.p.) with an Alzet mini-pump for one day.
Result:	Resulted in 72% tumor growth inhibition (TGI) on day 7 relative to vehicle at 7.5 mg/kg dose (in the B16 model). Resulted in only 22% TGI (at the 1 mg/kg daily dosing for five days) (in the B16 model). Did not result in inhibition of xenograft tumor growth relative to vehicle at day 17 when administered intraperitoneally at a dose of 2.5 mg/kg for 24 hours (in the OVCAR-3 model). Resulted in 50% regression at single 5 mg/kg dose (i.v.) (in the OVCAR-3 model). Showed median time to tumor volume of 1500 mm³: 28.5 days (2.5 mg/kg/day i.p. group); > 39 days (5 mg/kg i.v. group).

Clinical Trial

分子量

279.34

Formula

C₁₇H₁₇N₃O

CAS 号

827031-83-4

性状

固体

颜色

Light yellow to yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (357.99 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5799 mL	17.8993 mL	35.7987 mL
5 mM	0.7160 mL	3.5799 mL	7.1597 mL
10 mM	0.3580 mL	1.7899 mL	3.5799 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.45 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.45 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.45 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.34%

选择批次：

Data Sheet (632 KB) SDS (393 KB)

COA (289 KB) HNMR (189 KB) LCMS (119 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]

[2]. Kasibhatla S, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res. 2007 Jun 15;67(12):5865-71. [Content Brief]

[3]. Jones J T, et al. Comparison of MPC-6827 activity in xenograft models with different dosing schedules. Journal of Clinical Oncology, 2011, 29(15_suppl): e13080-e13080.

Verubulin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5799 mL	17.8993 mL	35.7987 mL	89.4967 mL
	5 mM	0.7160 mL	3.5799 mL	7.1597 mL	17.8993 mL
	10 mM	0.3580 mL	1.7899 mL	3.5799 mL	8.9497 mL
	15 mM	0.2387 mL	1.1933 mL	2.3866 mL	5.9664 mL
	20 mM	0.1790 mL	0.8950 mL	1.7899 mL	4.4748 mL
	25 mM	0.1432 mL	0.7160 mL	1.4319 mL	3.5799 mL
	30 mM	0.1193 mL	0.5966 mL	1.1933 mL	2.9832 mL
	40 mM	0.0895 mL	0.4475 mL	0.8950 mL	2.2374 mL
	50 mM	0.0716 mL	0.3580 mL	0.7160 mL	1.7899 mL
	60 mM	0.0597 mL	0.2983 mL	0.5966 mL	1.4916 mL
	80 mM	0.0447 mL	0.2237 mL	0.4475 mL	1.1187 mL
	100 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8950 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Verubulin827031-83-4MPC 6827MPC6827MPC-6827Microtubule/TubulinB16OVCAR-3melanomaovarian cancerMCF-7A549Inhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Verubulin (Synonyms: MPC 6827)

Customer Review

Other Forms of Verubulin:

Verubulin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Verubulin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Verubulin (Synonyms: MPC 6827)

Customer Review

Other Forms of Verubulin:

Verubulin 相关抗体

Verubulin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Verubulin 相关抗体:

摩尔计算器

稀释计算器

Verubulin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z